APA

Tinoco J. C., Pavia-Ruz N., Cruz-Valdez A., Aranza Doniz C., Chandrasekaran V., Dewé W., Liu A., Innis B. L. & Jain V. K. (20140820). Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. : Vaccine.

Chicago

Tinoco Juan Carlos, Pavia-Ruz Noris, Cruz-Valdez Aurelio, Aranza Doniz Carlos, Chandrasekaran Vijayalakshmi, Dewé Walthère, Liu Aixue, Innis Bruce L and Jain Varsha K. 20140820. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. : Vaccine.

Harvard

Tinoco J. C., Pavia-Ruz N., Cruz-Valdez A., Aranza Doniz C., Chandrasekaran V., Dewé W., Liu A., Innis B. L. and Jain V. K. (20140820). Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. : Vaccine.

MLA

Tinoco Juan Carlos, Pavia-Ruz Noris, Cruz-Valdez Aurelio, Aranza Doniz Carlos, Chandrasekaran Vijayalakshmi, Dewé Walthère, Liu Aixue, Innis Bruce L and Jain Varsha K. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. : Vaccine. 20140820.